Bryan L. Roth MD, PhD is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. Trained as a Psychiatrist and biochemist, Dr. Roth has published more than 400 papers in the general area of the molecular pharmacology of drug actions, including a large number of papers published in Science, Nature and Cell over the past decade. Among Dr. Roth’s major discoveries include the discovery of the 5-HT2B serotonin receptor as the molecular target responsible for drug-induced valvular heart disease, the discovery of the kappa-opioid receptor as the molecular target for salvinorin A’s psychoactive actions and the development and validation of the widely used chemogenetic technology DREADDs (Designer Receptors Exclusively Activated by Designer Drugs). Dr. Roth has received a number of honors including the Goodman and Gilman Award for Receptor Pharmacology (ASPET; 2016) and election to the National Academy of Medicine of the National Academy of Sciences (2014). Dr. Roth also given many endowed lectures focused on pharmacology including the Goodman, Koppyani and Philip S. Portoghese Lectures. Dr. Roth has also been named a Thompson Reuters ‘Highly Cited Scientist’ in Pharmacology and in Biology and Biochemistry.